Attenuation of cold stress-induced exacerbation of cardiac and adipose tissue pathology and metabolic disorders in a rat model of metabolic syndrome by the glucocorticoid receptor antagonist RU486

Nutrition and Diabetes

Volumn 6, Issue 4, 2016, Pages

  Nagasawa, K ^a   Matsuura, N ^a   Takeshita, Y ^a   Ito, S ^a   Sano, Y ^a   Yamada, Y ^a   Uchinaka, A ^a   Murohara, T ^b   Nagata, K ^a  

^a Department of Pathophysiological Laboratory Sciences ^*  (Japan)

^b NAGOYA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

11BETA HYDROXYSTEROID DEHYDROGENASE 1; GLUCOCORTICOID RECEPTOR; LEPTIN RECEPTOR; MIFEPRISTONE;

ADIPOSE TISSUE; ANIMAL; ANTAGONISTS AND INHIBITORS; COLD; DAHL RAT; DISEASE MODEL; DRUG EFFECTS; FIBROSIS; GLUCOSE INTOLERANCE; HEART; HYPERTROPHY, LEFT VENTRICULAR; MALE; METABOLIC SYNDROME X; METABOLISM; PATHOLOGY; PATHOPHYSIOLOGY; PHYSIOLOGICAL STRESS; RAT; ZUCKER RAT;

11-BETA-HYDROXYSTEROID DEHYDROGENASE TYPE 1; ADIPOSE TISSUE; ANIMALS; COLD TEMPERATURE; DISEASE MODELS, ANIMAL; FIBROSIS; GLUCOSE INTOLERANCE; HEART; HYPERTROPHY, LEFT VENTRICULAR; MALE; METABOLIC SYNDROME X; MIFEPRISTONE; RATS; RATS, INBRED DAHL; RATS, ZUCKER; RECEPTORS, GLUCOCORTICOID; RECEPTORS, LEPTIN; STRESS, PHYSIOLOGICAL;

EID: 84988483836     PISSN: None     EISSN: 20444052     Source Type: Journal    
DOI: 10.1038/NUTD.2016.14     Document Type: Article

References (51)

1. Rosmond R, Dallman MF, Bjorntorp P. Stress-related cortisol secretion in men: relationships with abdominal obesity and endocrine, metabolic and hemody-namic abnormalities. J Clin Endocrinol Metab 1998; 83: 1853–1859.
2. Mikurube H, Kaneko M, Murata C, Komaki Y, Ishikawa N, Higashiyama R et al. Association of change in the type of job with prevalence of components of the metabolic syndrome-special reference to job stress. [Nihon koshu eisei zasshi] Jpn J Public Health 2005; 52: 987–993.
3. Pacak K, Palkovits M. Stressor specificity of central neuroendocrine responses: implications for stress-related disorders. Endocr Rev 2001; 22: 502–548.
4. Arnaldi G, Angeli A, Atkinson AB, Bertagna X, Cavagnini F, Chrousos GP et al. Diagnosis and complications of Cushing's syndrome: a consensus statement. J Clin Endocrinol Metab 2003; 88: 5593–5602.
5. Wang M. The role of glucocorticoid action in the pathophysiology of the metabolic syndrome. Nutr Metab (Lond) 2005; 2: 3.
6. Morton NM, Seckl JR. 11 Beta-hydroxysteroid dehydrogenase type 1 and obesity. Obes Metab 2008; 36: 146–164.
7. Staab CA, Maser E. 11Beta-hydroxysteroid dehydrogenase type 1 is an important regulator at the interface of obesity and inflammation. J Steroid Biochem Mol Biol 2010; 119: 56–72.
8. Evans RM. The steroid and thyroid hormone receptor superfamily. Science 1988; 240: 889–895.
9. fa rat. Nutr Diabetes 2011; 1: e1.
10. fa rats: a new animal model of metabolic syndrome. Hypertens Res 2012; 35: 186–193.
11. Takeshita Y, Watanabe S, Hattori T, Nagasawa K, Matsuura N, Takahashi K et al. Blockade of glucocorticoid receptors with RU486 attenuates cardiac damage and adipose tissue inflammation in a rat model of metabolic syndrome. Hypertens Res 2015; 38: 741–750.
12. Kuo LE, Kitlinska JB, Tilan JU, Li LJ, Baker SB, Johnson MD et al. Neuropeptide Y acts directly in the periphery on fat tissue and mediates stress-induced obesity and metabolic syndrome. Nat Med 2007; 13: 803–811.
13. Hattori T, Murase T, Iwase E, Takahashi K, Ohtake M, Tsuboi K et al. Glucocorticoid-induced hypertension and cardiac injury: effects of mineralocorticoid and glucocorticoid receptor antagonism. Nagoya J Med Sci 2013; 75: 81–92.
14. Rickard AJ, Funder JW, Fuller PJ, Young MJ. The role of the glucocorticoid receptor in mineralocorticoid/salt-mediated cardiac fibrosis. Endocrinology 2006; 147: 5901–5906.
15. Takatsu M, Hattori T, Murase T, Ohtake M, Kato M, Nashima K et al. Comparison of the effects of cilnidipine and amlodipine on cardiac remodeling and diastolic dysfunction in Dahl salt-sensitive rats. J Hypertens 2012; 30: 1845–1855.
16. Kato MF, Shibata R, Obata K, Miyachi M, Yazawa H, Tsuboi K et al. Pioglitazone attenuates cardiac hypertrophy in rats with salt-sensitive hypertension: role of activation of AMP-activated protein kinase and inhibition of Akt. J Hypertens 2008; 26: 1669–1676.
17. Hattori T, Murase T, Takatsu M, Nagasawa K, Matsuura N, Watanabe S et al. Dietary salt restriction improves cardiac and adipose tissue pathology independently of obesity in a rat model of metabolic syndrome. J Am Heart Assoc 2014; 3: e001312.
18. Miyata K, Rahman M, Shokoji T, Nagai Y, Zhang GX, Sun GP et al. Aldosterone stimulates reactive oxygen species production through activation of NADPH oxidase in rat mesangial cells. J Am Soc Nephrol 2005; 16: 2906–2912.
19. Matsuura N, Asano C, Nagasawa K, Ito S, Sano Y, Minagawa Y et al. Effects of pioglitazone on cardiac and adipose tissue pathology in rats with metabolic syndrome. Int J Cardiol 2015; 179: 360–369.
20. Nagata K, Somura F, Obata K, Odashima M, Izawa H, Ichihara S et al. AT1 receptor blockade reduces cardiac calcineurin activity in hypertensive rats. Hypertension 2002; 40: 168–174.
21. Sakata Y, Yamamoto K, Mano T, Nishikawa N, Yoshida J, Hori M et al. Activation of matrix metalloproteinases precedes left ventricular remodeling in hypertensive heart failure rats: its inhibition as a primary effect of angiotensin-converting enzyme inhibitor. Circulation 2004; 109: 2143–2149.
22. Nagata K, Obata K, Xu J, Ichihara S, Noda A, Kimata H et al. Mineralocorticoid receptor antagonism attenuates cardiac hypertrophy and failure in low-aldosterone hypertensive rats. Hypertension 2006; 47: 656–664.
23. Yamada T, Nagata K, Cheng XW, Obata K, Saka M, Miyachi M et al. Long-term administration of nifedipine attenuates cardiac remodeling and diastolic heart failure in hypertensive rats. Eur J Pharmacol 2009; 615: 163–170.
24. Xu J, Nagata K, Obata K, Ichihara S, Izawa H, Noda A et al. Nicorandil promotes myocardial capillary and arteriolar growth in the failing heart of Dahl salt-sensitive hypertensive rats. Hypertension 2005; 46: 719–724.
25. Kuo LE, Czarnecka M, Kitlinska JB, Tilan JU, Kvetnansky R, Zukowska Z. Chronic stress, combined with a high-fat/high-sugar diet, shifts sympathetic signaling toward neuropeptide Y and leads to obesity and the metabolic syndrome. Ann N Y Acad Sci 2008; 1148: 232–237.
26. Walker BR, Phillips DIW, Noon JP, Panarelli M, Andrew R, Edwards HV et al. Increased glucocorticoid activity in men with cardiovascular risk factors. Hypertension 1998; 31: 891–895.
27. Reynolds RM, Walker BR, Syddall HE, Andrew R, Wood PJ, Whorwood CB et al. Altered control of cortisol secretion in adult men with low birth weight and cardiovascular risk factors. J Clin Endocrinol Metab 2001; 86: 245–250.
28. Filipovsky J, Ducimetiere P, Eschwege E, Richard JL, Rosselin G, Claude JR. The relationship of blood pressure with glucose, insulin, heart rate, free fatty acids and plasma cortisol levels according to degree of obesity in middle-aged men. J Hypertens 1996; 14: 229–235.
29. Kotsis V, Stabouli S, Papakatsika S, Rizos Z, Parati G. Mechanisms of obesity-induced hypertension. Hypertens Res 2010; 33: 386–393.
30. Zhang Y, Chan MM, Andrews MC, Mori TA, Croft KD, McKenzie KU et al. Apocynin but not allopurinol prevents and reverses adrenocorticotropic hormone-induced hypertension in the rat. Am J Hypertens 2005; 18: 910–916.
31. Hu L, Zhang Y, Lim PS, Miao Y, Tan C, McKenzie KU et al. Apocynin but not L-arginine prevents and reverses dexamethasone-induced hypertension in the rat. Am J Hypertens 2006; 19: 413–418.
32. Hall JE, da Silva AA, do Carmo JM, Dubinion J, Hamza S, Munusamy S et al. Obesity-induced hypertension: role of sympathetic nervous system, leptin, and melanocortins. J Biol Chem 2010; 285: 17271–17276.
33. Esler M, Straznicky N, Eikelis N, Masuo K, Lambert G, Lambert E. Mechanisms of sympathetic activation in obesity-related hypertension. Hypertension 2006; 48: 787–796.
34. Matsuura N, Nagasawa K, Minagawa Y, Ito S, Sano Y, Yamada Y et al. Restraint stress exacerbates cardiac and adipose tissue pathology via beta-adrenergic signaling in rats with metabolic syndrome. Am J Physiol Heart Circ Physiol 2015; 308: H1275–H1286.
35. Dhuper S, Abdullah RA, Weichbrod L, Mahdi E, Cohen HW. Association of obesity and hypertension with left ventricular geometry and function in children and adolescents. Obesity 2011; 19: 128–133.
36. Lister K, Autelitano DJ, Jenkins A, Hannan RD, Sheppard KE. Cross talk between corticosteroids and alpha-adrenergic signalling augments cardiomyocyte hyper-trophy: a possible role for SGK1. Cardiovasc Res 2006; 70: 555–565.
37. 2+current. J Mol Cell Cardiol 1999; 31: 1551–1558.
38. Melendez GC, McLarty JL, Levick SP, Du Y, Janicki JS, Brower GL. Interleukin 6 mediates myocardial fibrosis, concentric hypertrophy, and diastolic dysfunction in rats. Hypertension 2010; 56: 225–231.
39. Bradham WS, Bozkurt B, Gunasinghe H, Mann D, Spinale FG. Tumor necrosis factor-alpha and myocardial remodeling in progression of heart failure: a current perspective. Cardiovasc Res 2002; 53: 822–830.
40. Weber KT. From inflammation to fibrosis: a stiff stretch of highway. Hypertension 2004; 43: 716–719.
41. Takatsu M, Nakashima C, Takahashi K, Murase T, Hattori T, Ito H et al. Calorie restriction attenuates cardiac remodeling and diastolic dysfunction in a rat model of metabolic syndrome. Hypertension 2013; 62: 957–965.
42. Walker BR. Glucocorticoids and cardiovascular disease. Eur J Endocrinol 2007; 157: 545–559.
43. Wilckens T, De Rijk R. Glucocorticoids and immune function: unknown dimensions and new frontiers. Immunol Today 1997; 18: 418–424.
44. McKenna NJ, Lanz RB, O'Malley BW. Nuclear receptor coregulators: cellular and molecular biology. Endocr Rev 1999; 20: 321–344.
45. Hermoso MA, Matsuguchi T, Smoak K, Cidlowski JA. Glucocorticoids and tumor necrosis factor alpha cooperatively regulate Toll-like receptor 2 gene expression. Mol Cell Biol 2004; 24: 4743–4756.
46. Vandevyver S, Dejager L, Tuckermann J, Libert C. New insights into the anti-inflammatory mechanisms of glucocorticoids: an emerging role for glucocorticoid-receptor-mediated transactivation. Endocrinology 2013; 154: 993–1007.
47. Rose AJ, Vegiopoulos A, Herzig S. Role of glucocorticoids and the glucocorticoid receptor in metabolism: insights from genetic manipulations. J Steroid Biochem Mol Biol 2010; 122: 10–20.
48. Masuzaki H, Paterson J, Shinyama H, Morton NM, Mullins JJ, Seckl JR et al. A transgenic model of visceral obesity and the metabolic syndrome. Science 2001; 294: 2166–2170.
49. Masuzaki H, Yamamoto H, Kenyon CJ, Elmquist JK, Morton NM, Paterson JM et al. Transgenic amplification of glucocorticoid action in adipose tissue causes high blood pressure in mice. J Clin Invest 2003; 112: 83–90.
50. Montague CT, O'Rahilly S. The perils of portliness: causes and consequences of visceral adiposity. Diabetes 2000; 49: 883–888.
51. Kamei N, Tobe K, Suzuki R, Ohsugi M, Watanabe T, Kubota N et al. Overexpression of monocyte chemoattractant protein-1 in adipose tissues causes macrophage recruitment and insulin resistance. J Biol Chem 2006; 281: 26602–26614.